New drug HY07121 enters human trials for Hard-to-Treat cancers
NCT ID NCT06639256
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a new drug called HY07121 in 258 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV infusion. The main goals are to check safety, find the right dose, and see if it can shrink tumors. This is an early-stage trial, so results are not guaranteed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HY07121 (a drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early (Phase 1/2) trial with only 258 participants, so the drug may not prove effective or safe enough for wider use. Side effects, including serious ones, are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••